Heart & Brain Lab, Western University
London, Ontario, N6A 5A5, Canada
NCT Number: NCT05791617
Patients with stroke have a 25x higher risk of cardiovascular complications within the first 30 days of the event compared to individuals without stroke. The mechanisms behind these complications are not well understood. Evidence suggests that inflammation plays a central role. With the present proof-of-concept prospective cohort study, the investigators aim to demonstrate that patients develop cardiac inflammation after stroke by performing positron emission tomography (PET) magnetic resonance imaging (MRI) of the heart within 15 days after stroke. As a secondary aim, the investigators will evaluate whether post-stroke cardiac inflammation persists at 3 months after stroke. The control group will be comprised of age- and sex-matched individuals without stroke.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
London, Ontario, N6A 5A5, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will undergo cardiac PET/MRI scanning at 30±5 days and at 90±5 days post-stroke.
Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 30±5 days and at 90±5 days post-stroke
Other names: Olink® Target-96 inflammatory biomarker panel
NT-proBNP is useful both in the diagnosis and prognosis of heart failure and is considered to be a gold standard biomarker in heart failure. Measurement of NT-proBNP on patients' blood samples at 30±5 days and at 90±5 days post-stroke
Other names: N-terminal prohormone of brain natriuretic peptide
Time frame: At 30 days±5 post stroke
Cardiac inflammation as measure on PET/MR scanning.
Time frame: At 90±5 days compared to first 30 days±5 post-stroke
Cardiac inflammation as measure on PET/MR scanning.
Time frame: At 90±5 days compared to first 30±5 days post stroke
Change in levels of NT-proBNP and HS-TnT between 30±5 and 90±15 days post-stroke.
Time frame: At 90±5 days compared to first 30±5 days
Systemic inflammatory markers will be measured using a high-performance biomarker panel for the following 92 proteins (all of which will be informed in pg/mL):
ADA; ARTN; AXIN1; NGF; CCL13; CCL19; CCL2; CCL20; CCL23; CCL25; CCL28; CCL3; CCL4; CCL7; CCL8; CXCL10; CXCL11; CXCL5; CXCL6; CXCL9; CDCP1; CASP8; CST5; DNER; CCL11; EIF4EBP1; FGF19; FGF21; FGF23; FGF5; FLT3LG; CX3CL1; GDNF; CXCL1; HGF; IFNG; IL1A; IL10; IL10RA; IL10RB; IL12B; IL13; IL15RA; IL17A; IL17C; IL18; IL18R1; IL2; IL2RB; IL20; IL20RA; IL22RA1; IL24; IL33; IL4; IL5; IL6; IL7; CXCL8; MMP1; KITLG; LIF; LIFR; LTA; CSF1; SIRT2; CD244;NTF3;NRTN;OSM;CD274;S100A12;TGFA;STAMBP;SLAMF1;MMP10;SULT1A1;CD6;CD5;CD8A;TSLP;TGFB1;TNF;TNFSF10;TNFSF11;TNFSF12;TNFSF14;TNFRSF11B;CD40;TNFRSF9;PLAU;VEGFA
Luciano A. Sposato
Other
Acronym: PEPSI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03892265
Alcohol Drinking, Alcohol Use, Unspecified
Port-au-Prince, West, Haiti
View Trial DetailsNCT05746221
Brain Diseases, Brain Infarction
Nijmegen, Netherlands
View Trial DetailsNCT00387712
Behavior, Brain Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT02878772
Brain Diseases, Cardiovascular Diseases
View Trial Details